Kevin Sayer is the president, chairman, and CEO of Dexcom, a company that develops, manufactures, and distributes continuous glucose monitoring systems.
Sayer joined Dexcom as its president and chief operating officer in 2011, and he became CEO in 2015. In his various roles, he has directed research and development, manufacturing, regulatory, clinical, finance, marketing, and sales functions.
He has played a leading role in developing new technologies in the United States and Europe, including the Dexcom G5 Mobile CGM System and the Dexcom G4 PLATINUM System with Share, among others.
Before joining Dexcom, Sayer was the chief financial officer for medical technology company, Biosensors International. He has also served as an independent healthcare and medical technology industry consultant, as the executive vice president and CFO for Specialty Laboratories, and as the CFO of MiniMed from 1994 until 2001, when it was acquired by Medtronic.
Sayer was recognized on Forbes’ “Innovative Leaders” list in 2019.
He earned both his B.S. and M.S. in accounting and information systems at Brigham Young University.
What is Kevin R. Sayer's net worth?
The estimated net worth of Kevin R. Sayer is at least $38.20 million as of April 8th, 2024. Mr. Sayer owns 283,893 shares of DexCom stock worth more than $38,200,642 as of April 16th. This net worth estimate does not reflect any other investments that Mr. Sayer may own. Additionally, Mr. Sayer receives an annual salary of $2,220,000.00 as CEO at DexCom. Learn More about Kevin R. Sayer's net worth.
How old is Kevin R. Sayer?
What is Kevin R. Sayer's salary?
How do I contact Kevin R. Sayer?
Has Kevin R. Sayer been buying or selling shares of DexCom?
Who are DexCom's active insiders?
DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?
During the last twelve months, insiders at the medical device company sold shares 43 times. They sold a total of 306,582 shares worth more than $39,797,231.65. The most recent insider tranaction occured on April, 8th when CEO Kevin R Sayer sold 49,633 shares worth more than $6,864,243.90. Insiders at DexCom own 0.4% of the company.
Learn More about insider trades at DexCom. Information on this page was last updated on 4/8/2024.
